Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-2CAR: Biomarker-Guided Dual-Target CAR-T in Solid Tumors
NCT07523529Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Apr 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous dual-target CAR-T cells (Beijing Biotech) in solid tumor, sponsored by Biotech Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
autologous dual-target CAR-T cells (Beijing Biotech)
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07523529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07523529.